EnteroMedics
Saint Paul
About EnteroMedics
EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $161.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2017)
- Ticker: nasdaq:ETRM
- Website: enteromedics.com
- Phone: (800) 698-2562
Industries & Categories
Biotechnology, Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/enteromedics-193034 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.